I suffer from Fibromyalgia, spinal stenosis, osteoporosis, arthritis, and 66 yeas of wear and tear. I was overwhelmed by the endless varieties of hemp oil even after reading all the product info, so I chose to go with Amazon’s pick.this has a subtle mint flavor and within 2days, I was seeing a reduction in pain, better mood, and improvements in my brain fog. They have a loyal customer now. Even the headache I have had for 6 months since being put on Gabapentin is gone which means I no longer take Advil like tic tacs! Click Here For CBD
The existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See Sativex Commences US Phase II/III Clinical Trial in Cancer Pain and GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome ).
In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [1, 2].

Over the years, cannabis oil has been used as an effective treatment for anxiety and depression. Furthermore, it is constantly being researched by scientists. In fact, CBD effects on anxiety is currently considered to be one of the most intriguing and well-funded areas of modern cannabis research; if progress continues in the way that it has over the last several years, then it is very possible that we will develop highly effective ways in which oils for anxiety (and depression) can be used as an effective therapy.


So far, I am very pleased with this product. I have been trying this product to address issues I have dealt with for many years now. With laws the way they are right now, I am very pleased to be able to pursue this course of treatment, which is mainly anxiety, mild panic attacks...... I still can say for certain, but the CBD method seems to be working for me. And I'm going to continue on this path of addressing my issues, as my doctor would, if laws allowed him to.
Cannabidiol (CBD) is a naturally-occurring constituent of industrial hemp (cannabis sativa) plants. It is the most abundant non-psychoactive cannabinoid found in cannabis and is being scientifically investigated for numerous reasons. Most people have heard of a cannabinoid called THC, which is the ingredient in cannabis that gets users high. Unlike THC, CBD (cannabidiol) is a non-psychoactive cannabinoid and does not cause a high.
According to the National Eczema Association, “Cannabinoids represent an exciting prospect for the future of AD therapy. With measurable anti-itch, anti-pain, anti-microbial and anti-inflammatory properties, the effect of cannabinoids in patients with AD has already begun to be demonstrated.” (10) Cannabinoids can be found in both cannabis oil and CBD oil.
I rely heavily on chiropractic care and medications. And, yet, the one, almost laughable thing I didn’t know about was hemp oil. When my friend told me she was a representative for a hemp oil company, and thought it would be helpful for my peripheral neuropathy at night, I just stood there with my mouth open. I had no idea about what it was or how it differed from medical marijuana, even.
A condition in which a transplant attacks the body (Graft-versus-host disease (GVHD)). Graft-versus-host disease is a complication that can occur after a bone marrow transplant. In people with this condition, donor cells attack the person's own cells. Early research shows that taking cannabidiol daily starting 7 days before bone marrow transplant and continuing for 30 days after transplant can extend the time it takes for a person to develop GVHD.

This is a critical area for new research. While there is preliminary evidence that CBD may have therapeutic value for a number of conditions, we need to be careful to not get ahead of the evidence. Ninety-five percent of drugs that move from promising preclinical findings to clinical research do not make it to market. The recently announced elimination of the PHS review of non-federally funded research protocols involving marijuana is an important first step to enhance conducting research on marijuana and its components such as CBD. Still, it is important to try to understand the reasons for the lack of well-controlled clinical trials of CBD including: the regulatory requirements associated with doing research with Schedule I substances, including a requirement to demonstrate institutional review board approval; and the lack of CBD that has been produced under the guidance of Current Good Manufacturing Processes (cGMP) – required for testing in human clinical trials – available for researchers. Furthermore, the opportunity to gather important information on clinical outcomes through practical (non-randomized) trials for patients using CBD products available in state marijuana dispensaries is complicated by the variable quality and purity of CBD from these sources.


According to the National Eczema Association, “Cannabinoids represent an exciting prospect for the future of AD therapy. With measurable anti-itch, anti-pain, anti-microbial and anti-inflammatory properties, the effect of cannabinoids in patients with AD has already begun to be demonstrated.” (10) Cannabinoids can be found in both cannabis oil and CBD oil.
Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner.[25][26] In vitro, cannabidiol inhibited receptors affecting the activity of voltage-dependent sodium and potassium channels, which may affect neural activity.[27] A small clinical trial reported that CBD partially inhibited the CYP2C-catalyzed hydroxylation of THC to 11-OH-THC.[28]
These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose, treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious medical condition.
^ Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (December 2005). "Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract". Ther Drug Monit. 27 (6): 799–810. PMID 16306858.
It is also illegal to market CBD oil as a dietary supplement.  This is because cannabidiol is not a food ingredient (dietary ingredient) and it doesn’t have an established safety profile or history of use in the food supply. If you see a CBD product, and it is labelled as a dietary supplement, then the company is either unaware or doesn’t care about the FDA’s current position that CBD is not a legitimate dietary ingredient.
One of the most experienced practitioners in this field is Los Angeles physician Bonni Goldstein, who has used the compound to treat dozens of children with intractable epilepsy. She says about half of these patients have seen a significant drop in the number of seizures. “Used in the right way, with the right patient, CBD is extremely powerful,” she says.
CBD and THC interact with our bodies in a variety of ways. One of the main ways they impact us is by mimicking and augmenting the effects of the compounds in our bodies called “endogenous cannabinoids” - so named because of their similarity to the compounds found in the cannabis plant. These “endocannabinoids” are part of a regulatory system called the “endocannabinoid system”.
×